Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
Veneno Technologies Co. Ltd.
Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels, GPCRs, and transporters. | Veneno Technologies is a Japan-origin deep-tech biotech company founded in 2020 and built around a proprietary Disulfide-Rich Peptide, or DRP, discovery platform. Based on scientific achievements originating from AIST, the company has established an integrated end-to-end system combining design, screening, functional evaluation, and production of DRPs through its proprietary Veneno Suite and PERISS platform. Veneno aims to create a new peptide modality for targets that have remained difficult to address with conventional small molecules or antibodies. The company’s core strength lies in its ability to translate the intrinsic biological advantages of naturally occurring DRPs into an industrial discovery engine. Because DRPs possess multiple disulfide bonds and a conformationally constrained structure, they can offer high stability, protease resistance, thermal robustness, and strong target selectivity. These properties make DRPs especially attractive for membrane proteins and other challenging target classes where conventional modalities often face limitations in selectivity, penetration, or functional control. Veneno is leveraging this differentiated biology to generate novel therapeutic candidates with the potential to open new mechanisms of action in previously hard-to-drug disease areas. Current Strategic Focus Areas 1) Ri-DRP drug discovery: Veneno is actively advancing Ri-DRP programs in which DRPs are conjugated with radioactive payloads, including alpha-emitting isotopes. By combining the high target selectivity and compact size of DRPs with radiopharmaceutical design, the company aims to enable precise tumor targeting and differentiated payload delivery beyond what is often achievable with conventional antibody-based radioconjugates or small-molecule radiopharmaceuticals. Ri-DRP represents a highly strategic direction for Veneno, particularly in oncology, where target-specific delivery, tissue distribution, and therapeutic precision are central to next-generation drug design. 2) Functional development of DRPs as next-generation antibody-like molecules: Veneno positions DRPs not simply as peptides, but as a next-generation functional modality that can complement and, in selected settings, outperform antibodies. The compact and highly structured nature of DRPs allows precise interaction with biologically important surfaces while maintaining strong stability and selectivity. This creates opportunities in areas where antibodies may be constrained by tissue penetration, epitope accessibility, or molecular size. Veneno is therefore developing DRPs as next-generation antibody-like agents for membrane proteins, complex interaction interfaces, and disease areas that require finely tuned molecular recognition. 3) DRP drug discovery for membrane proteins including ion channels, GPCRs, and transporters: Veneno’s discovery platform is particularly differentiated in the generation of functional DRPs against membrane proteins that have historically been difficult to drug. Through the proprietary PERISS method, the company can identify inhibitor, activator, and binder DRPs for ion channels, GPCRs, transporters, and related membrane targets. These target classes are biologically important across oncology, inflammation, pain, cardiometabolic disorders, and other major therapeutic areas, yet they remain challenging because small molecules can suffer from off-target effects and antibodies often have limited access to the relevant target surfaces. Veneno is using DRPs to bridge this gap and unlock first-in-class opportunities in membrane protein drug discovery. Through these three focus areas, Veneno Technologies is positioning DRPs as a scalable platform for next-generation therapeutics spanning membrane protein drug discovery, antibody-like functional molecules, and radiopharmaceutical innovation. At BIO International 2026, the company is seeking global collaboration opportunities including joint research, co-development, licensing, and strategic partnerships with pharmaceutical companies, biotech innovators, radiopharmaceutical developers, and research institutions.
Van Heron Labs
. | Van Heron Labs (VHL) The Cellular Intelligence Layer for Life Sciences Booth #1611 | vanheronlabs.com | contact@vanheronlabs.com — Van Heron Labs is transforming how biological processes are designed, optimized, and scaled. VHL has built the most powerful cellular intelligence engine ever created — the only end-to-end, multi-omic digital twin platform designed exclusively for cellular optimization. At the core of VHL’s platform is a proprietary system that decodes complete cellular biology — gene expression, metabolism, stress responses, and biomolecular needs across 17 molecular categories spanning thousands of compounds — and translates that data into a real-time biological digital twin. VHL identifies and predicts the impact of every critical biomolecule: metabolites, ions, trace metals, minerals, cofactors, growth factors, cytokines, ECM components, and more. The result: VHL customers see breakthrough improvements in titer, viability, potency, and manufacturability — faster and at a fraction of the cost of traditional R&D. Proven across cell therapy, biologics, precision fermentation, and more: T cell therapies (CD4/CD8, TIL, Treg): 80% improved viability, 40% increase in activation, FOXP3 stability for greater potency — saving $25K–$60K per batch iPSC programs: ~25 critical ingredients identified, many absent from any commercial media — 10X cheaper than internal R&D, 5 months faster to clinic MSC programs: ~30 critical ingredients identified, resolving stress pathways and improving scale-up reliability — unlocking $25–80M in potential new media product revenue HEK / bioprocessing: 40–200% proliferation improvement, 900% cell density gains with process optimization, 360% higher protein titer Microbial (E. coli, B. subtilis, P. aeruginosa): 200–400% proliferation increases, 200–360% higher titer, fully defined bioreactor media. How you can work with VHL: VHL offers four flexible engagement models — Analytics Only (1-week turnaround), Process Development Recommendations (1–2 weeks), Co-Development (3–10 weeks), and Strategic Partnerships for long-term innovation. All engagements begin with RNA-Seq or proteomics data and deliver interactive, publication-quality multi-omics reports, biological digital twins, and actionable recommendations your team can execute immediately. Backed by NVIDIA, Microsoft, and AWS, and trusted by dozens of life science companies, large and small. Who we’re looking to meet at BIO 2026: VHL is actively seeking strategic partnerships with CDMOs, CROs, reagent and culture media manufacturers, and asset-focused companies looking to improve manufacturing performance, reduce R&D burden, develop proprietary formulations, and unlock new revenue streams through the power of cellular intelligence. Want to connect before San Diego? Schedule a meeting or platform demo with CEO & Founder Rebecca Vaught, Ph.D. at calendly.com/rvaught-vanheronlabs/30min — or stop by Booth #1611 and meet us in person. We’d love to show you what cellular intelligence can do for your program.
Vacino Biotech Co., Ltd.
Vacino Biotech focuses on innovations for HLA-peptide based vaccine (9-mer peptide), nucleic acid medicine (microRNA) and brain delivery technology (targeting peptide) for the indication of infectious disease, neurodegenerative disease and oncology. Core products: Oral universal COVID vaccine against SARS-CoV-2 variants A microRNA-based anti-neuroinflammation therapeutics A brain shuttled anti-Her2 antibody for treating the peripheral and intracranial tumors. An oral bioavailable brain-targeting LNP for delivering the oligonucleotide and large molecule therapeutics Show less Description (NOTE: Given time constraints & strategic priorities, we will not be meeting with CMOs, CROs, service companies, etc. at the meeting) Founded in July 2020, Vacino Biotech is committed to the development of novel nucleic acid drugs and universal vaccines. With the self-developed next-generation vaccine design SED technology, we have invested in the development of COVID-19 T-cell vaccine products to solve the situation of rapid mutation of the new coronavirus variants. In addition, it has invested in the development of nucleic acid drugs for the treatment of Alzheimer’s disease and a cutting-edge efficient brain delivery technology to increase the content of brain treatment drugs and prevent the occurrence of diseases at an early stage. ● Core products and platform technology Oral universal COVID-19 vaccine: VACINO-CO is a novel oral universal antigen vaccine designed to protect against most COVID-19 viruses and related variants. Through the activation of T cells, it can eliminate virus-infected cells, which can effectively inhibit recurrence and the phenomenon of seroconversion. The innovative and convenient oral dosage form can be applied to the elderly and children in vulnerable groups to obtain safer and effective immunity, safe and effective immune protection of the population. It is currently about to enter human clinical trials. MicroRNA-based Alzheimer’s Disease Drug Developments: Patented Vacino-ADmir is a microRNA-based drug that inhibits neuroinflammation through the PD1/PDL1 mechanism associated with inflammation and can be treated from the source of the disease, which is different from the symptomatic treatment on the market. It can be applied to dementia and neuroinflammation-related diseases. GMP manufacturing is currently underway. High-Performance Brain Delivery Platform Technology: The patented Vacino-BT target peptide can be co-transported by binding to transferrin receptors through transcytosis, with a brain delivery rate of more than 20 % a 1-hour post-injection, which is far superior to other brain delivery technologies on the market. At present, it has been successfully applied to antibodies and lipid nanoparticles. GoBrain LNP: Based VBT technology, we developed VBT-lipid conjugates that can enable LNP having brain targeting capability. HerBrain and eHerbrain platform: Based on VBT technology, we developed chemically modified anti-Her2 antibody and novel DNA-engineered anti-Her2 antibody, which allows brain shuttle capability and tissue penetration.
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
SigutLabs s.r.o.
SigutLabs, a contract research organization (CRO) located in Prague, Czech Republic, helps businesses from small start-ups to pharmaceutical giants overcome their chemistry challenges. Our agile PhD chemists specialize in custom synthesis, scale-up, and contract research across organic, bioorganic, and medicinal chemistry, with a focus on nucleotide and nucleoside chemistry, ADC linkers, and advanced applications. We excel at developing novel synthetic routes for undescribed compounds and custom synthesis of known molecules, also offering dedicated FTE chemists. We have a lean team of up to 10 employees with every chemist holding a PhD degree, which is an industry-leading scientific staff ratio. All our experts studied at prestigious universities and have extensive experience in organic and medicinal chemistry from top international institutions. Our cutting-edge labs prioritize a sustainable future with eco-friendly practices and invest in top-tier equipment to handle your most complex projects. Products from our inventory are available for purchase through our e-shop, ensuring super-fast and secure delivery worldwide. Founded in 2011, SigutLabs has grown from a small lab to a partner of choice for leading pharmaceutical and Silicon Valley companies. We played a major role in the fight against COVID-19 by developing a new synthetic pathway of remdesivir for research in just four months, and were recognized for our achievements with the 2023 Company of the Year award (Central Bohemia region). Fueled by a vision to build on the legacy of Czech chemistry, exemplified by Prof. Antonín Holý and his groundbreaking molecule tenofovir, we aim to re-establish the Czech Republic’s position on the global chemistry map. We can tackle your toughest challenges with our team’s diverse chemistry experience, including: ADC linkers Heterocyclic chemistry Palladium-catalyzed reactions Organometallic chemistry Nucleoside/nucleotide chemistry Fluorine chemistry Photochemistry Supramolecular chemistry Total synthesis of natural products Modification of enzyme substrates/inhibitors Visit our website at www.sigutlabs.com to see how SigutLabs frees hands, saves costs, and accelerates your projects with our outsourced chemistry expertise. Follow us on LinkedIn to see the latest news. | x
Shanghai OPM Biosciences Co., Ltd
OPM Biosciences (Stock Code: 688293) is a leading provider of Cell Culture Media (CCM) and CDMO (Contract Development and Manufacturing Organization) services. We offer an integrated solution to meet the needs of biopharmaceutical companies worldwide. OPM was established in 2013 dedicated to total cell culture solution development, which has resulted in our fast growth. We are proud to be the first listed CCM company in China and committed to being a total solution provider in biologics development. Our management system is certified to ISO9001:2015 by TÜV NORD. We have four fully cGMP-compliant plants, covering an overall area of 18,000m². Currently, we are constructing a new 30,000m² headquarters to meet the growing demand for our products and services. OPM is becoming a strategic partner of biopharmaceutical companies worldwide, and our dedication to quality and innovation ensures that we continue to be a trusted partner in the industry. Our CCM solutions are renowned for their innovative chemically-defined/serum-free media design and manufacturing. We offer a range of products and services, including proprietary commercial media, customized formulations, and OEM solutions for our clients’ unique cell lines. Our exceptional performance has established us as the preferred supplier for over 230 biologics (IND or BLA) worldwide. In addition, OPM’s CDMO services provide efficient End-to-End solutions for biotherapeutic protein development and manufacturing. Our cGMP-compliant facilities support all stages of biologics development, from antibody discovery to IND and BLA manufacturing up to 2000L. Our dedicated team of experienced scientists is committed to excellence and has contributed to the development of over 200 biologics, supporting global clients in achieving successful IND applications with the FDA and NMPA.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
Pharmigene Inc
Established in 2005, Pharmigene Inc. is a leading biotechnology company specializing in pharmacogenomic testing. We hold exclusive global licenses from Academia Sinica for patents related to genetic testing for Warfarin and other critical medications such as Carbamazepine and Allopurinol. Leveraging these proprietary technologies, we have developed advanced diagnostic products and tools that have secured comprehensive technical patent certifications across numerous countries worldwide, including the USA, Europe, New Zealand, Australia, Japan, China, India, and Southeast Asia.Headquartered in Taiwan, Pharmigene operates a state-of-the-art R&D center and maintains stringent quality management systems. Our commitment to excellence is underscored by our certifications, including international ISO 13485, Taiwan QMS (GMP), and South Korea KGMP, ensuring the highest standards in medical device manufacturing and diagnostic solutions.
NOF CORPORATION
NOF CORPORATION is the leading commercial supplier of drug delivery products such as activated PEGs, lipids and ultrapure Polysorbate 80. Our cutting edge products include Pendant type single molecule PEG linkers for ADCs and SS-lipids for nucleic acid/gene delivery and vaccines.